News | April 07, 2025
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Subscribe To Our Newsletter & Stay Updated
